Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Carmen Fava, Paola Berchialla, PhD, Jessica Petiti, PhD, Maria Teresa Bochicchio, Barbara Izzo, PhD, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, PhD, Giovanna Rege Cambrin, MD PhD, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Alessandro Martino, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD, Daniela Cilloni, MD PhD, Enrico Marco Gottardi

Blood (2019) 134 (Supplement_1): 2092.

https://doi.org/10.1182/blood-2019-125614

Published: 2019

Journal Articles

An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease

Filomena Daraio, PhD, Emilia Giugliano, Carmen Fava, MD PhD, Roberta Lorenzatti, Dr., Marta Varotto, Dr., Davide Barberio, Dr., Simona Bernardi, PhD, Barbara Izzo, PhD, Santa Errichiello, PhD, Maria Teresa Bochicchio, Claudia Venturi, Dr., Francesco Albano, MD, Giuseppe Saglio, MD PhD, Fabrizio Pane, MD, Giovanni Martinelli, MD, Giorgina Specchia, MD, Domenico Russo, MD, Enrico Marco Gottardi, Dr.

Blood (2017) 130 (Supplement 1): 4176.

https://doi.org/10.1182/blood.V130.Suppl_1.4176.4176

Published: 2017

Journal Articles

One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study

Filomena Daraio, PhD, Maria Teresa Bochicchio, Dr., Barbara Izzo, PhD Prof., Claudia Venturi, Dr., Santa Errichiello, PhD, Francesca Crasto, Dr., Giovanna Rege-Cambrin, MD, Roberta Lorenzatti, Dr., Carmen Fava, MD, Fausto Castagnetti, MD, Fabrizio Pane, MD Prof., Giovanni Martinelli, MD Prof., Giuseppe Saglio, MD Prof., Enrico Marco Gottardi, Dr.

Blood (2016) 128 (22): 5423.

https://doi.org/10.1182/blood.V128.22.5423.5423

Published: 2016

Journal Articles

Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib

Blood (2015) 126 (23): 1570.

https://doi.org/10.1182/blood.V126.23.1570.1570

Published: 2015

Journal Articles

A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia

Novella Pugliese, MD Graduate student, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Laura Cella, PhD, Santa Errichiello, PhD, Luana Marano, Simona Caruso, Graduate student, Nicola Esposito, Barbara Izzo, PhD, Marco Picardi, MD, Vincenzo Martinelli, MD, Fabrizio Pane, MD

Blood (2014) 124 (21): 1850.

https://doi.org/10.1182/blood.V124.21.1850.1850

Published: 2014

Journal Articles

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

Maria Teresa Bochicchio, Barbara Izzo, Enrico Gottardi, Biagio De Angelis, Roberta Lorenzatti, Claudia Venturi, Francesca Crasto, Caterina De Benedittis, Filomena Daraio, Emanuela Ottaviani, Alessandro Volpengo, Giuseppe Saglio, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD

Blood (2014) 124 (21): 1809.

https://doi.org/10.1182/blood.V124.21.1809.1809

Published: 2014

Journal Articles

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Susan Branford, PhD, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, PhD, Yu Jin, Richard C. Woodman, MD, Fabrizio Pane, MD, Dong-Wook Kim, Jerald P. Radich, MD, Timothy P. Hughes

Blood (2010) 116 (21): 889.

https://doi.org/10.1182/blood.V116.21.889.889

Published: 2010

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Blood (2009) 114 (22): 2212.

https://doi.org/10.1182/blood.V114.22.2212.2212

Published: 2009

Journal Articles

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

Nicola Esposito, PhD, Fabrizio Quarantelli, Luigia Luciano, MD, Barbara Izzo, PhD, Anna Lucia Peluso, PhD, Marco Picardi, MD, Susan Branford, PhD, D.L. White, PhD, Timothy Hughes, PhD, Jerald Radich, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giuseppe Saglio, MD, Thea Kalebic, PhD, Mark Thornquist, PhD, Giovanni Martinelli, MD, Fabrizio Pane, MD

Blood (2008) 112 (11): 1106.

https://doi.org/10.1182/blood.V112.11.1106.1106

Published: 2008

Journal Articles

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

Nicola Esposito, PhD, Irene Colavita, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Luigia Luciano, MD, Luigi Del Vecchio, MD, Timothy Hughes, Jerald Radich, Domenico Russo, MD, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Junia Melo, MD, PhD, Margherita Ruoppolo, PhD, Thea Kalebic, Fabrizio Pane, MD

Blood (2008) 112 (11): 3186.

https://doi.org/10.1182/blood.V112.11.3186.3186

Published: 2008

Journal Articles

Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.

Nicola Esposito, PhD, Fabrizio Quarantelli, PhD, Barbara Izzo, PhD, Giada Muccioli Casadei, MD, Luigia Luciano, MD, Giuseppe Saglio, MD, Junia V. Melo, MD, Thea Kalebic, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD

Blood (2007) 110 (11): 1014.

https://doi.org/10.1182/blood.V110.11.1014.1014

Published: 2007

Journal Articles

Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.

Giuliana Alimena, MD, Massimo Breccia, MD, Luigia Luciano, MD, Fabrizio Quarantelli, PhD, Daniela Diverio, PhD, Barbara Izzo, MD, Biagio De Angelis, Marco Mancini, MD, Roberto Latagliata, MD, Ida Carmosino, MD, Mauro Nanni, PhD, Bruno Rotoli, MD, Franco Mandelli, MD, Fabrizio Pane, MD

Blood (2006) 108 (11): 2158.

https://doi.org/10.1182/blood.V108.11.2158.2158

Published: 2006

Journal Articles

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

Blood (2005) 106 (11): 375.

https://doi.org/10.1182/blood.V106.11.375.375

Published: 2005

Journal Articles

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

Blood (2004) 104 (13): 4245–4251.

https://doi.org/10.1182/blood-2004-03-0826

Published: 2004

Journal Articles

Efficacy and Safety of Imatinib Treatment in Elederly Patients with Chronic Myeloid Leukemia.

Bruno Martino, MD, Iolanda Vincelli, MD, Francesca Ronco, MD, Bruno Modafferi, MD, Domenica Princi, PhD, Fortunato Morabito, MD, Barbara Izzo, MD, Fabrizio Pane, MD, Francesco Nobile, MD

Blood (2004) 104 (11): 4680.

https://doi.org/10.1182/blood.V104.11.4680.4680

Published: 2004

Journal Articles

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Simona Bassi, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Barbara Giannini, BD, Daniela Cilloni, MD, Barbara Izzo, BD, Antonio De Vivo, MD, Simona Luatti, BD, Nicoletta Testoni, BD, Giovanna Rege-Cambrin, MD, Ilaria Iacobucci, BD, Enrico Gottardi, BD, Fabrizio Pane, MD, Francesco Salvatore, MD, Alessandra Dorigo, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2004) 104 (11): 2935.

https://doi.org/10.1182/blood.V104.11.2935.2935

Published: 2004

Journal Articles

Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.

Blood (2004) 104 (11): 4672.

https://doi.org/10.1182/blood.V104.11.4672.4672

Published: 2004

NARROW

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease

One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study

Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib

A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia

Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment

Down-Modulation of Shp1 and Hsp70 Provides a Survival Advantage to the Ph+ Cells of CML Patients Additive to That Related to the Oncogenic BCR/ABL Protein and May Account for Resistance to Ima Treatment.

Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

Efficacy and Safety of Imatinib Treatment in Elederly Patients with Chronic Myeloid Leukemia.

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only